With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Quote this valuation with its source: Fair value, Potential value and the price at analysis.
FAQ
DHR — frequently asked questions
Is Danaher Corporation overvalued?
In our latest published analysis dated 2026-09-25, DHR looks meaningfully overvalued. The price recorded at analysis is USD 224 versus our fair value of USD 187; the high endpoint is presented separately as potential value of USD 206. That implies roughly 16.7% downside to fair value at that date.
Our latest published report, analyzed 2026-09-25, gives DHR a fair value of USD 187 and a potential value of USD 206. The conclusion is triangulated across multiple valuation models and weighted by reliability for Danaher Corporation's archetype; it is a dated research output, not a live price.
Should I buy DHR now?
Our latest published rating for DHR, analyzed 2026-09-25, is Reduce. Danaher Corporation looks meaningfully overvalued at the analysis-date price of USD 224 versus fair value of USD 187; potential value is USD 206. This is research for educational purposes, not personalized investment advice.
What are the biggest risks for DHR?
The dedicated bear-case section in our report analyzed 2026-09-25 documents Danaher Corporation's material risks, evidence, thresholds, and thesis-invalidation conditions. Scenario-specific explanations remain in that section so the report does not repeat or decontextualize them elsewhere.
What is DHR's rating?
Our latest published rating for DHR, analyzed 2026-09-25, is Reduce, with a published moat assessment of 9/10 (Wide). It reflects our fair value of USD 187, the potential value of USD 206, and the price recorded at analysis (USD 224).
The most significant upside catalyst is an accelerated clearing of customer facility commissioning bottlenecks, allowing deferred chromatography resin shipments (> $100M) to deliver early in FY2027 alongside mid-teens bioprocessing order conversion and commercial batch manufacturing ramps,.
Danaher Corporation (NYSE: DHR) receives a Reduce rating. While Danaher maintains wide economic moats rooted in regulatory switching costs across Cytiva bioprocessing consumables and entrenched clinical diagnostics platforms, the market is pricing in an aggressive margin recovery that leaves no margin of safety against ongoing customer facility commissioning deferrals and endemic respiratory testing normalization.3
Against the market price of $223.90 as of 2026-09-25, the stock trades at an implied upside of -16.67% (a 20.00% valuation premium). At 23.81x NTM forward earnings, the current valuation assumes immediate operational reacceleration and rapid margin expansion toward 28.5%, discounting the execution friction associated with customer facility readiness and product normalization.3
Operational Trends and Segment Drivers: In Biotechnology ($7,293M FY2025 revenue, $1,864M operating income),, underlying consumables and equipment orders are expanding at mid-teens rates. However, customer plant readiness challenges and production schedule revisions delayed multiple large chromatography resin shipments ($10M-$30M each, totaling >$100M) out of Q2/Q3 and into FY2027,. Concurrently, the Diagnostics segment ($9,941M FY2025 revenue, $2,650M operating income), contends with a 250 bps top-line drag in Q3 2026 from Cepheid respiratory testing normalization against a guided full-year baseline of about $1.6B.4,7
Cash Generation and Capital Allocation: Danaher continues to demonstrate robust fundamental quality governed by the Danaher Business System (DBS). In FY2025, the company generated $6,416M in operating cash flow and $5,260M in free cash flow, alongside a strong balance sheet holding $4,615M in cash. Capital intensity remains disciplined, with capital expenditures of $1,156M (4.71% of revenue),. This cash engine enabled the strategic, early-closing acquisition of StatLab and ongoing share repurchases, supporting our modeled diluted share reduction of -1.83% CAGR,.4,5,6
Valuation Synthesis: Our synthesized fair value of $186.58 is anchored primarily on discounted earnings ($203.44 midpoint, 35% weight) and multi-stage moat fade ($204.45 midpoint, 25% weight), balanced by owner earnings ($162.55 midpoint, 25% weight) and forward earnings ($157.49 midpoint, 15% weight) discounted at an 8.54% cost of equity. While long-term EPS compounding of 9.2% remains achievable, the current share price provides no margin of safety against potential execution delays in commercial biomanufacturing restarts or prolonged procurement headwinds in High Growth Markets ($7,022M in FY2025),.2,4,7
Regulatory Lock-In and High Switching Costs in Bioprocessing
Cytiva purification chromatography resins and filtration media are specified directly within FDA and EMA approved biologic drug master files (DMFs), creating multi-decade switching barriers and mid-teens order growth across consumables and equipment,.4
Diagnostics generated $9,941M in FY2025 revenue and $2,650M in operating income,, supported by high single-digit momentum across Leica Biosystems, Radiometer, and non-respiratory Cepheid test menus.4,7
Reduce. While Cytiva bioprocessing and Cepheid diagnostics possess wide economic moats, customer facility readiness deferrals pushing >$100M of resin shipments into FY2027, and respiratory testing normalization to $1.6B create an unfavorable risk-reward profile. Investors should reduce exposure and await a better margin of safety.3,4
Company overview
The manufacture of many of its products is a highly exacting and complex process, and if the company directlies or indirectly encounter problems manufacturing products, its business and financial statements could suffer. The manufacture of many of its products is a highly exacting and complex process, due in part to strict regulatory requirements.
A combined stress event evaluating a simultaneous 600 bps reduction in normalized operating margins, a 500 bps reduction in 5-year revenue growth, and a 20% multiple contraction demonstrates that Danaher's present valuation carries asymmetric downside. At $223.90, the stock trades 20.0% above the committee fair value midpoint of $186.58. While high free cash flow conversion ($5,260M in FY2025) and $4,615M in balance sheet cash mitigate insolvency risks, prolonged bioprocessing deferrals and respiratory drag leave no margin of safety for equity investors at prevailing trading levels.
Danaher's wide economic moat is underpinned by two primary structural sources: customer switching costs in bioprocessing consumables (Cytiva) and an entrenched razor-and-blade installed base in clinical diagnostics (Beckman Coulter, Cepheid, Leica Biosystems, Radiometer). In Biotechnology ($7,293M revenue in FY2025), chromatography resins and filtration media are specified directly into commercial biologic Drug Master Files (DMFs) approved by the FDA and EMA. Because substituting these consumables requires costly, multi-year clinical revalidation and regulatory re-filing, drug developers face immense switching barriers over the multi-decade commercial manufacturing lifecycle of approved therapies.
Diagnostics ($9,941M revenue, $2,650M operating income in FY2025,) operates under a razor-and-blade commercial architecture. Proprietary instrument placements—such as the DxI 9000 clinical analyzer at Beckman Coulter and GeneXpert systems at Cepheid —drive recurring reagent and consumable purchases across hospital networks and clinical reference laboratories. The high capital cost and workflow integration of automated instruments create substantial procedural switching barriers, securing predictable high-margin consumable streams that buffer macro cyclicality.
The highlighted cell is Fair value when every assumption sits at its base level ($186.58). Each row and column shows what Fair value becomes when one assumption moves.
A substantial beat driven by early bioprocessing resin shipment recognition and non-respiratory diagnostic expansion would validate faster operating margin recovery toward historical peak levels.
In-line
Maintain Reduce; Maintain trimmed portfolio weightings, verify bioprocessing backlog conversion milestones, and avoid deploying incremental capital above .
Industry benchmarks indicate a capex-to-revenue ratio of 4.5% and capex-to-depreciation of 0.80, demonstrating that the life sciences and bioprocessing equipment sector is operating at replacement levels following pandemic-era capacity overbuild. Danaher's FY2025 capex of $1,156M against revenue of $24,568M yields a 4.71% capex-to-revenue ratio,, aligning with this restrained reinvestment regime.6
Bull cycle
In an accelerating upcycle, biopharmaceutical capacity expansions resume aggressively, customer greenfield facilities come online ahead of schedule, chromatography resin pushouts (> $100M) convert fully into FY2027 deliveries, and Chinese hospital procurement re-accelerates, driving organic revenue growth above 8%,.
Bear cycle
In a protracted downcycle, pharmaceutical capital rationing persists, clinical trial delays defer commercial batch scale-up, and hospital equipment budgets freeze, capping consolidated core growth below 3% and keeping operating margins trapped in the low-20% range,.
§11 Position management
Sizing
0-1%
Under a Reduce rating with the market price ($223.90) trading at a 20.0% premium to the synthesized fair value of $186.58, capital allocation should be restricted to a minimal underweight posture. Investors should trim existing holdings toward a 0-1% portfolio allocation to limit downside risk while awaiting a more favorable entry valuation.3
Risk
Risk management focuses on capital preservation and downside limitation. With total debt of $27.86B, upcoming debt service is well insulated by $4.62B in cash and $5.26B in annual free cash flow,. However, portfolio risk stems from valuation vulnerability: Danaher's forward P/E of 23.81x leaves minimal cushion against shipment deferrals or macro healthcare spending pauses. Maintaining strict position weight limits (0-1%) and disciplined trim thresholds safeguards capital.
§12 Investor perspectives
Quality Compounder & Core Long-Term Investor
Hold
Long-term compounders with an attractive historical cost basis may hold core positions given Danaher's wide economic moats in Cytiva bioprocessing and Cepheid diagnostics, supported by $5.26B in annual free cash flow. However, fresh capital deployment should be paused until market price ($223.90) approaches fair value ($186.58),.3,5
Valuation-Sensitive & Tactical Investor
Avoid
Valuation-sensitive investors should avoid initiating new positions or actively trim existing holdings. Danaher trades at 23.81x forward earnings, representing a 20.00% premium to our $186.58 fair value midpoint. With >$100M of bioprocessing resin shipments pushed into FY2027 and ongoing respiratory headwinds, the near-term risk-reward is asymmetric to the downside.3,4
Total Return & Income-Oriented Investor
§14 Final recommendation
Action
Reduce
We recommend reducing exposure to Danaher Corporation (DHR). While Danaher commands wide economic moats in bioprocessing and diagnostics, the market has priced in a frictionless recovery to 28.5% operating margins and 8.04% top-line growth in FY2027.1,3
Near-term operational friction remains unaddressed by current valuation multiples. Biopharmaceutical customer facility readiness challenges have shifted more than $100M of high-margin chromatography resin shipments into FY2027,, while endemic respiratory testing deflation creates a 250 bps headwind in Q3,. At 23.81x NTM forward earnings, the risk-reward profile is skewed unfavorably, justifying a trim of existing positions to reallocate capital into assets with a wider margin of safety.
§15Your notes
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Private notes
Visible only to you. Synced to this device.
0 chars
Sources
The records this analysis drew on, as they stood when it was run.
Analyst consensusData as of 2026-09-25 · Published 2026-09-25 · Provider-adjusted · cited for 1 figureCited in Final recommendation
Danaher converted $6,416M in operating cash flow into $5,260M in free cash flow in FY2025,, funding accretive capital redeployment such as the early closing of StatLab and ongoing share repurchases.4,5,6
Bear
Probability
20%
Return
-30.1%
Path target
$156.41
Core revenue growth restricted to low single digits (<3.0%)4
High Growth Markets revenue contracts due to persistent VBP and hospital scrutiny7
Extended customer production schedule delays and site readiness challenges in biomanufacturing suppress Cytiva consumable volumes, while endemic respiratory testing falls below guided baselines and Chinese hospital procurement remains depressed,. Operating margins remain constrained near the FY2025 baseline of 19.09%, curtailing free cash flow growth.
Ways this thesis can break
Protracted bioprocessing resin deferrals and respiratory testing deflation hold operating margins at reported FY2025 baseline, preventing modeled normalization to 28.5%.
Under this kill scenario, biopharmaceutical customer site readiness bottlenecks persist past FY2027 and endemic respiratory testing revenue falls below the guided $1.6B baseline,. Consolidated operating margin stays suppressed near the FY2025 level of 19.09%, breaching the 22.5% trigger threshold and imposing an estimated 24.5% fair value impairment.4,6
FV impact
0%
Operating margin 6 points lower throughout
Trigger
Within 12 months
Prolonged biopharmaceutical customer facility readiness delays and China hospital procurement headwinds freeze consolidated core revenue growth at low single digits.
Persistent commissioning delays in biomanufacturing plants combined with ongoing centralized volume-based procurement and healthcare anti-corruption inspections across Chinese hospitals, constrain 5-year consolidated core revenue growth below the 3.0% trigger threshold, driving an estimated 28.0% fair value impairment.4,7
FV impact
-1.1%
Revenue and EPS growth 5 points lower for five years
Trigger
Within 24 months
Valuation derating toward historical and peer lower bounds as earnings growth fails to reaccelerate above GDP.
If earnings reacceleration stalls and Danaher's growth converges toward broader GDP expansion, market multiples derate from the current forward P/E of 23.81x toward the historical lower bound of 18.0x, generating a 20.0% fair value impairment.3
FV impact
-2.5%
Terminal multiple 20% lower
Trigger
Within 18 months
Early-warning signals to monitor
The five developments that would weaken our investment case.
Triggers pillar falsification for Diagnostics franchise, signaling pricing pressure or test deflation eroding core segment profitability.
Current:26.66% in FY2025 ($2,650M operating profit on $9,941M revenue),
Alert if< 24.0% in FY2026
The Danaher Business System (DBS) continuous improvement culture reinforces structural advantages through operational efficiency and disciplined integration of strategic bolt-ons, exemplified by the early closing and commercial rollout of StatLab. Operating cash flow generation of $6,416M and free cash flow of $5,260M in FY2025, provide the balance-sheet firepower to fund continuous R&D and targeted acquisitions, compounding the firm's competitive moat against peers like Thermo Fisher and Agilent.
Danaher's economic profit generation remains firmly positive, supported by FY2025 operating income of $4,690M and free cash flow of $5,260M on a capital expenditure base of $1,156M,,. With a computed WACC of 7.97% and cost of equity of 8.54%, the business comfortably earns returns in excess of its cost of capital. However, at the current enterprise valuation ($223.90 share price, $157.31B market cap,), the market price fully capitalizes these economic profits, creating a 20.0% valuation premium over the synthesized fair value of $186.58.2,3,5,6
9/ 10
Wide
Sources of advantage
01Bioprocessing Consumable Regulatory DMF Lock-In — Cytiva chromatography resins and filtration media are embedded into FDA/EMA biologic drug master files, creating prohibitive clinical re-validation costs,.Wide
02Clinical Diagnostics Installed Base and Proprietary Consumables — Entrenched diagnostic instruments generated $9,941M of revenue and $2,650M of operating income in FY2025 through multi-year proprietary reagent contracts,.Wide
03High Growth Markets Commercial and Clinical Distribution — Established commercial and clinical sales infrastructure generated $7,022M in High Growth Markets in FY2025 (28.6% of revenue).Moderate
Consolidated core revenue expands at 3%-4% in FY2026 and reaccelerates to 8.0% in FY2027 as customer batch manufacturing schedules normalize and deferred chromatography resin shipments deliver,. Operating margins progress from 19.09% in FY2025 to 26.5% in FY2026 and reach 28.5% over the forecast horizon,. Free cash flow conversion remains above 100%, funding debt service and regular share repurchases.4,5,6
China High Growth Markets core growth rebounds to 8%-10%7
StatLab and new 510(k) assays exceed accretion expectations4
Rapid absorption of bioprocessing inventory leads to accelerated commercial batch manufacturing and new greenfield quoting. Specialty diagnostics maintain high single-digit momentum driven by DxI 9000 and Cepheid non-respiratory assays, while China hospital procurement rebounds. Operating margins expand ahead of schedule, driving strong double-digit earnings growth.4
Results meeting management guidance confirm gradual multi-year normalization but leave valuation stretched at a premium to Fair value.
Miss
Downgrade the rating; Execute further reductions in portfolio exposure, audit bioprocessing order intake trends, and test liquidity buffers against downside scenarios.
A guidance cut or revenue miss signaling renewed bioprocessing cancellations or accelerated respiratory test erosion would trigger further valuation multiple compression toward historical troughs.
Earnings quality is high, evidenced by an FCF-to-net income conversion ratio exceeding 145% ($5,260M FCF on $3,614M net income in FY2025,). Operating earnings are backed by tangible cash collections across recurring diagnostic reagent and bioprocessing consumable contracts, with minimal reliance on non-cash adjustments.5,6
CurrentGuided to ~$1.6B full year baseline with headwinds abating in Q4,.
Why it matters
Determines when the 250 bps headwind in Q3 fully dissipates, allowing underlying core diagnostics growth to shine.4
04
Metric:
High Growth Markets and China Hospital Demand
CurrentManagement notes policy headwinds are beginning to lessen in late 2026.
Why it matters
High Growth Markets represent 28.6% of revenue ($7,022M in FY2025); easing of VBP and anti-corruption campaigns would unlock diagnostic instrument sales.7
05
Metric:
StatLab Acquisition Accretion and Menu Expansion
CurrentClosed early; tracking to add $0.07-$0.08 to FY2026 adjusted EPS.
Why it matters
Tests M&A deployment efficacy, new 510(k) assay launches, and high single-digit growth expectations,.4
Danaher demonstrates exceptional cash flow conversion, generating $6,416M in cash flow from operations and $5,260M in free cash flow in FY2025,. Capital expenditures of $1,156M represented just 4.71% of total revenue ($24,568M),, underscoring the asset-light nature of its consumable-heavy operating model. FCF conversion of net income ($3,614M in FY2025) exceeded 145%, supported by disciplined working capital management and stable non-cash depreciation of $2,447M.5,6
Management balances strategic M&A, debt deleveraging, and share repurchases. The early closing of the StatLab acquisition in 2026 adds $0.07-$0.08 to EPS and bolsters specialty diagnostics. Concurrently, share repurchases reduced diluted share count from 743.1M in FY2023 to 716.1M in FY2025 (-1.84% CAGR),, with shares outstanding standing at 702.99M as of September 2026. Total debt of $27.86B is supported by $4.62B in balance sheet cash, and robust annual free cash flow.
Returns on invested capital are trending upward from FY2025 trough levels as operating margins normalize from 19.09% toward the guided 26.5% Q3 baseline and long-term 28.5% target, driven by high-margin consumable mix recovery in Biotechnology ($1,864M operating profit in FY2025).
ROIC comfortably exceeds Danaher's computed WACC of 7.97% and cost of equity of 8.54%, confirming positive economic value creation across normalized operating cycles.
Biotechnology Margins Face Operational Leverage Recovery
Biotechnology delivered $1,864M of operating income on $7,293M of revenue (25.56% margin) in FY2025,, depressed from historic 30%+ levels.
Fulfillment of deferred resin shipments and mid-teens order growth will yield substantial operational margin expansion.
Diagnostics Acts as the Primary Operating Profit Engine
Diagnostics generated $2,650M in operating income on $9,941M revenue (26.66% margin) in FY2025,.
Diagnostics provides consistent cash flow ballast while Life Sciences and Biotechnology work through cyclical transitions.
Danaher Corporation (DHR) trades at 23.8x forward earnings against a peer median of 28.1x. Its EV/EBITDA of 22.5x compares with a peer median of 25.1x. The comparison uses 4 peers: Thermo Fisher Scientific Inc., Agilent Technologies Inc., Illumina Inc. and IDEXX Laboratories Inc., as of 2026-09-25.
Secular trends
Trend
Impact
Note
Biologics and Monoclonal Antibody Expansion
positive
Expanding global pipeline of biologic therapeutics and biosimilars drives multi-decade consumable demand for Cytiva purification resins and filtration media.
Centralized Hospital Procurement and Healthcare Cost Containment
negative
Government pricing controls, volume-based procurement (VBP), and hospital anti-corruption reviews in emerging markets compress diagnostic testing realization.
Positioning
Danaher is uniquely positioned as a high-margin consumables supplier (~80% recurring revenue base), mitigating capital equipment cyclicality through recurring reagent and chromatography media demand.4
Entry tranches
Level
Action
Why
Initiate initial tracking position
$170.01 - $186.58
Accumulate selectively on fundamental confirmation
Corresponds to the midpoint of synthesized intrinsic value ($186.58), contingent on verified acceleration in bioprocessing order conversions.
Reduce emerging market terminal contribution and trim long-term revenue CAGR assumption to 3.5%.
Avoid
With a modest dividend payout ($1.60 per share) and capital allocation focused on M&A and share repurchases, total returns are driven primarily by capital appreciation. At current prices, capital appreciation potential is negative (-16.67% implied upside to fair value),, making total return prospects unattractive until valuation multiples normalize.3
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
